Skip Ribbon Commands
Skip to main content
Menu
Clin Assoc Prof Ng Heng Joo

Clin Assoc Prof Ng Heng Joo

MBBS, MMed (Int Med), MRCP(UK), FRCPath(UK),FAMS

Head & Senior Consultant

Singapore General Hospital

Specialty: Haematology

Sub-specialties: Thrombosis and Haemostasis, Laboratory Haematology

Conditions Treated by this Doctor:
Acute Lymphocytic Leukemia (ALL), Acute Lymphocytic Leukemia (ALL), Aplastic Anaemia, Chronic lymphocytic leukemia, Chronic lymphocytic leukemia, Chronic Myeloid Leukemia (CML), Deep Vein Thrombosis, Deep Vein Thrombosis, Deep Vein Thrombosis, Deep Vein Thrombosis, essential thrombocythemia, Haemophilia and other bleeding disorders, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic Syndromes, Myelofibrosis, Polycythemia Vera, Pulmonary Embolism, Pulmonary Embolism, Thalassaemia, Thalassaemia.

Clinical Appointments

  • Head & Senior Consultant Haematology Singapore General HospitalSingapore General Hospital
  • Director, Patient Safety Singapore General HospitalSingapore General Hospital
  • Senior Consultant SingHealth Duke-NUS Blood Cancer Centre

Profile

Dr Ng received his early medical training at the National University of Singapore and then served in Malaysia before qualifying as an internal medicine specialist. He then joined the Department for his advanced specialty training in haematology before pursuing subspecialty training in coagulation, a branch of haematology dealing with blood clotting and bleeding disorders.

He is currently the Head of the department.

Dr Ng has a special interest in thrombotic and bleeding disorders. His research activities cover clinical aspects of managing these patients and laboratory diagnostics into coagulation disorders. 

Education

Professional Appointments and Committee Memberships

  • ​Director, Patient Safety and Clinica Standards Unit, Singapore General Hospital
  • Visiting Consultant, Blood Services Group, Health Sciences Authority

Awards

Research Interests

Publications

  • Abdul-Halim NA, Ng HJ. Bullous pemphigoid is a common associated disorder with acquired haemophilia A. Int J Hematol. 2021 Jan;113(1):58–62.
  • Lee LH, Nagarajan C, Tan CW, Ng HJ. Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review. Front Cardiovasc Med [Internet]. 2021;8:669288. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34095258
  • Ong SY, Tan CW, Ramya V, Malik AA, Lee XH, Hwang JCC, et al. Risk factors and predictors of treatment responses and complications in immune thrombocytopenia. Ann Hematol [Internet]. 2021 Mar;100(3):645–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33515047
  • Pravin RR, Huang BX, Sultana R, Tan CW, Goh KJ, Chan M-Y, et al. Mortality Trends of Oncology and Hematopoietic Stem Cell Transplant Patients Supported on Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. J Intensive Care Med. 2021 Aug;8850666211021561.
  • Santagostino E, Lalezari S, Reding MT, Ducore J, Ng HJ, Poulsen LH, et al. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A. Vol. 27, Haemophilia : the official journal of the World Federation of Hemophilia. England; 2021. p. e559–62.
  • Tan CW, Fan BE, Teo WZY, Tung ML, Shafi H, Christopher D, et al. Low incidence of venous thrombosis but high incidence of arterial thrombotic complications among critically ill COVID-19 patients in Singapore. Thromb J. 2021 Mar;19(1):14.
  • Tan CW, Tan JY, Wong WH, Cheong MA, Ng IM, Conceicao EP, et al. Clinical and laboratory features of hypercoagulability in COVID-19 and other respiratory viral infections amongst predominantly younger adults with few comorbidities. Sci Rep [Internet]. 2021;11(1):1793. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33469056
  • Tan JY, Conceicao EP, Wee LE, Ng HJ, Venkatachalam I. Low incidence of non-COVID-19 community respiratory viral infections amongst adults with haematological malignancies during the COVID-19 pandemic. Journal of internal medicine. England; 2021.
  • Tan JY, Tan CW, Wong WH, Cheong MA, Lee LH, Kalimuddin S, et al. Post-hospitalization venous thromboembolism in COVID-19 patients: Evidence against routine post-hospitalization prophylactic anticoagulation. Int J Lab Hematol [Internet]. 2021 Jun 19; Available from: http://www.ncbi.nlm.nih.gov/pubmed/34146452
  • Tan RY, Pang SC, Tng ARK, Ng HJ, Teh SP, Tan SG, et al. Effect of short-term low molecular weight heparin on patency following successful salvage of arteriovenous access with recurrent thrombosis. Nephrology (Carlton). 2021 Apr;26(4):350–7.
  • Tan CW, Ho LP, Kalimuddin S, Cherng BPZ, Teh YE, Thien SY, et al. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B(12) in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition. 2020;79–80:111017.
  • Tan CW, Low JGH, Wong WH, Chua YY, Goh SL, Ng HJ. Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability. Vol. 95, American journal of hematology. 2020. p. E156–8.
  • Tan CW, Wong WH, Cheen MHH, Chu YMH, Lim SS, Ng LCK, et al. Assessment of aPTT-based clot waveform analysis for the detection of haemostatic changes in different types of infections. Sci Rep. 2020 Aug;10(1):14186.
  • Ang AL, Wong WH, Tan J, Ng HJ, Tan CW, Kuperan P, et al. Ex vivo haemostatic capacity of plasma upon thawing and beyond: a comparison between fresh frozen plasma (FFP) and frozen plasma prepared from whole blood stored at room temperature up to 24 hours postcollection (RTFP24). Vox Sang. 2019 Apr;114(3):198–206.
  • Santagostino E, Lalezari S, Reding MT, Ducore J, Ng HJ, Poulsen LH, et al. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Thromb Res. 2019 Nov;183:13–9.
  • Tan CW, Cheen MHH, Wong WH, Wu IQ, Chua BLW, Ahamedulla SH, et al. Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism. Biochem medica. 2019 Jun;29(2):20710.
  • Tan CW, Wong WH, Idros R, Chan YH, Kaur H, Tng ARK, et al. Role of platelets in thrombin generation amongst patients with non-transfusion-dependent thalassaemia. Ann Hematol. 2019 Apr;98(4):861–8.
  • Tay HM, Lai YF, Kong MC, See E, Yeang SH, Koh SK, et al. Generational performance of three point-of-care testing devices compared with standard laboratory measurement of the international normalised ratio across extended ranges. J Clin Pathol. 2019 Apr;72(4):311–5.
  • Yan DT, Heng RGK, Ng HJ. Massive Spontaneous Haemothorax after Rivaroxaban Therapy for Acute Pulmonary Embolism. Eur J case reports Intern Med [Internet]. 2019;6(10):001236. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31742199
  • Ong SY, Ng HJ. Howell-Jolly bodies in systemic amyloidosis. Vol. 108, International journal of hematology. Japan; 2018. p. 119–20.
  • Phipps C, Lee YS, Ying H, Nagarajan C, Grigoropoulos N, Chen Y, et al. The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 Oct;59(10):2336–41.
  • Tan CW, Wong WH, Tan CK, Chan YH, Kaur H, Lee LH, et al. The Influence of Race on Plasma Thrombin Generation In Healthy Subjects In Singapore. Clin Appl Thromb  Off J Int  Acad Clin Appl Thromb. 2018 Oct;24(7):1144–7.
  • Fung FY, Wong WH, Ang SK, Koh HL, Kun MC, Lee LH, et al. A randomized, double-blind, placebo- controlled study on the anti-haemostatic effects of Curcuma longa, Angelica sinensis and Panax ginseng. Phytomedicine. 2017 Aug;32:88–96.
  • Kaur H, Yeang SH, See E, Grant D, Tan CW, Wong WH, et al. Reversal of rivaroxaban using Prothromplex Total, a 4-factor prothrombin complex. Vol. 156, Thrombosis research. United States; 2017. p. 117–8.
  • Mya HT, Linn YC, Lim LC, Ng HJ. Chronic NK lymphocytosis identified by a distinct immunophenotypic pattern. Vol. 105, International journal of hematology. Japan; 2017. p. 3–4.
  • Ong SY, Chin YA, Than H, Tan CW, Yap ES, Wong WH, et al. Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence. Vol. 96, Annals of hematology. Germany; 2017. p. 525–7.
  • Ong SY, Ho LP, Yeo PM, Ng HJ, Ang AL. Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia  with t(8;21). Vol. 106, International journal of hematology. Japan; 2017. p. 149–50.
  • Lai YF, Neo JK, Cheen MH, Kong MC, Tai BC, Ng HJ. Comparison of Medication Adherence and Treatment Persistence between New Oral Anticoagulant and Warfarin among Patients. Ann Acad Med Singapore. 2016 Jan;45(1):12–7.
  • Mya HT, Tay HM, Gan SW, Surendran S, Yeang SH, Lim CC, et al. Screening frequency, incidence and pattern of heparin-induced thrombocytopenia syndrome at a large tertiary institution. Int J Hematol. 2016 Jul;104(1):92–8.
  • Ong PYS, Koomanan N, Cheen MHH, Lai YF, Lim SH, Kong MC, et al. Real-World Impact of Setting a Narrow International Normalized Ratio Target Range in the Management of Older Adult Patients on Warfarin. Clin Appl Thromb  Off J Int  Acad Clin Appl Thromb. 2016 Sep;22(6):528–34.
  • Wong WH, Yip CY, Sum CL, Tan CW, Lee LH, Yap ES, et al. A Practical Guide to Ordering and Interpreting Coagulation Tests for Patients on Direct Oral Anticoagulants in Singapore. Ann Acad Med Singapore. 2016 Mar;45(3):98–105.
  • Yeang SH, Chan A, Tan CW, Lim ST, Ng HJ. Incidence and Management of Toxicity Associated with LAsparaginase in the Treatment of ALL and NK/TCell Lymphoma: an Observational Study. Asian Pac J Cancer Prev. 2016;17(7):3155–60.
  • Than H, Loh JBE, Sum CLL, Ng HJ. Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report. Vol. 68, Journal of clinical pathology. England; 2015. p. 318–9.
  • Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y. Patient-reported health preferences of anticoagulant-related outcomes. J Thromb Thrombolysis. 2015 Oct;40(3):268–73.
  • Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res. 2014 Apr;133(4):550–4.
  • Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. Cardiovasc drugs Ther. 2014 Dec;28(6):575–85.
  • Ng HJ, Chee YL, Ponnudurai K, Lim LC, Tan D, Tay JC, et al. Consensus recommendations for preventing and managing bleeding complications associated with novel oral anticoagulants in singapore. Ann Acad Med Singapore. 2013 Nov;42(11):593–602.
  • Linn Y-C, Yong H-X, Niam M, Lim T-J, Chu S, Choong A, et al. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy. 2012 Aug;14(7):851–9.
  • Lee LH, Liu TC, Kuperan P, Tan LK, Tan D, Poon ML, et al. Hereditary thrombophilia in an unselected cohort of venous thrombosis patients in Singapore. J Clin Pathol. 2011 Sep;64(9):814–7.
  • Koh SK, Ng HJ, Kong MC, Chan YH, Lee LH. Validity of current recommendation for peri-operative interruption of warfarin in Asians. J Thromb Thrombolysis. 2010 Oct;30(3):354–7.
  • Lee HY, Ng HJ, Wong PCA, Pang SM. Therapy-related leukemia cutis after adjuvant chemotherapy in a breast cancer patient. Vol. 90, Acta dermato-venereologica. Sweden; 2010. p. 649–50.
  • Tay LK, Lim FL, Ng HJ, Lee H-Y, Pang S-M, Thirumoorthy T. Cutaneous follicular hyperkeratotic spicules--the first clinical sign of multiple myeloma progression or relapse. Int J Dermatol. 2010 Aug;49(8):934–6.
  • Ang AL, Kuperan P, Ng CH, Ng HJ. Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost. 2009 May;101(5):852–9.
  • Letchumanan P, Ng H-J, Lee L-H, Thumboo J. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford). 2009 Apr;48(4):399–403.
  • Ng HJ, Lee LH. Trends in prevalence of deep venous thrombosis among hospitalised patients in an Asian institution. Thromb Haemost. 2009 Jun;101(6):1095–9.
  • Ng HJ, Lee LH. Haemophilia in 21st century Singapore. Ann Acad Med Singapore. 2009 Apr;38(4):372–8.
  • Tan CS, Chan KP, Chuah CT, Ng HJ, Cheah FK, Teo FS, et al. Life threatening and occult mediastinal haemorrhage secondary to acquired factor VIII deficiency. Vol. 38, Annals of the Academy of Medicine, Singapore. Singapore; 2009. p. 280–1.
  • Kong MC, Lim TG, Ng HJ, Chan YH, Lee LH. Feasibility, cost-effectiveness and patients’ acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic. Ann Hematol. 2008 Nov;87(11):905–10.
  • Ng HJ, Tan DCL, Yiu RC, How GF. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder. Leuk Res. 2008 Jan;32(1):169–71.
  • Phipps C, Ng HJ. Upper limb deep vein thrombosis and portable computer games. Am J Med. 2008 Jun;121(6):e3.
  • Koh L-P, Chen C-S, Tai B-C, Hwang WYK, Tan L-K, Ng H-Y, et al. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Biol blood marrow Transplant J Am Soc Blood Marrow Transplant. 2007 Jul;13(7):790–805.
  • Ng HJ, Crowther MA. Malignancy-associated venous thrombosis with concurrent warfarin-induced skin necrosis, venous limb gangrene and thrombotic microangiopathy. Thromb Haemost. 2006 Jun;95(6):1038–9.
  • Ng HJ, Crowther MA. Azathioprine and inhibition of the anticoagulant effect of warfarin: evidence from a case report and a literature review. Am J Geriatr Pharmacother. 2006 Mar;4(1):75–7.
  • Ng HJ, Crowther MA. New anti-thrombotic agents: emphasis on hemorrhagic complications and their management. Semin Hematol. 2006 Jan;43(1 Suppl 1):S77-83.
  • Ng HJ, Lee LH. Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients. Vasc Health Risk Manag. 2006;2(4):433–40.
  • Ng HJ, Crowther MA. Anticoagulation therapy in the antiphospholipid syndrome: recent advances. Curr Opin Pulm Med. 2005 Sep;11(5):368–72.
  • Ng HJ, Loh SM, Tan DCL, Lee LH. Thrombosis associated with the use of recombinant activated factor VII: profiling two events. Thromb Haemost. 2004 Dec;92(6):1448–9.
  • Ng HJ, Lee LH. Heparin-induced thrombocytopenia: acknowledging its presence in low-molecular weight heparin therapy. Int J Hematol. 2003 Feb;77(2):185–7.

Research Trials